Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing

Genome editing has therapeutic potential for treating genetic diseases and cancer. However, the currently most practicable approaches rely on the generation of DNA double-strand breaks (DSBs), which can give rise to a poorly characterized spectrum of chromosome structural abnormalities. Here, using...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature genetics 2021-06, Vol.53 (6), p.895-905
Hauptverfasser:	Leibowitz, Mitchell L., Papathanasiou, Stamatis, Doerfler, Phillip A., Blaine, Logan J., Sun, Lili, Yao, Yu, Zhang, Cheng-Zhong, Weiss, Mitchell J., Pellman, David
Format:	Artikel
Sprache:	eng
Schlagworte:	14/19 14/63 45/23 631/1647/1513 631/208 631/208/212 631/208/514 631/80 Abnormalities Agriculture Anemia, Sickle Cell - genetics Animal Genetics and Genomics Antigens, CD34 - metabolism Biomedical and Life Sciences Biomedicine Blood diseases Cancer Cancer Research Cell cycle Cell Division Chromosome rearrangements Chromosomes Chromosomes, Human - genetics Chromothripsis Congenital diseases CRISPR CRISPR-Associated Protein 9 - metabolism CRISPR-Cas Systems - genetics Deoxyribonucleic acid DNA DNA Cleavage DNA damage Editing Gene Editing Gene Function Gene sequencing Genes Genome editing Genome, Human Genomes Human chromosome abnormalities Human Genetics Humans Micronuclei Micronucleus, Germline - genetics Risk factors Sickle cell disease Tumor Suppressor Protein p53 - metabolism Whole genome sequencing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!